Current issues in prostate cancer

Current issues highlight some of the latest research into prostate cancer, new therapies becoming available and new drug treatments coming to the market.

Satraplatin retards the progression of hormone resistant, advanced prostate cancer In the last few years, there has been an increasing number of chemotherapy drugs that have shown usefulness in advancing prostate cancer (resistant to hormone therapies). Taxotere and mitozantrone...
Post-operative radiotherapy is now standard care in T3 disease In a randomised SWOG trial presented at the 47th meeting of the American Society for Therapeutic Radiology, 425 men with positive margins in the surgical resection specimen after radical...
PSA velocity prior to prostatectomy is prognostic A recent study reported from California looked at the rise in the blood/serum PSAprior to surgery for early prostate cancer. The authors found where there was a rise of more than 2ng/ml/year the...
Improving selection of patients for prostate biopsy There is a real, clinically challenging question as to when to perform a prostate biopsy on men whose blood levels of PSA are slightly raised above the upper limit of 4 but under 10. A recent...
Long term cure rates after permanent radio-isotope brachytherapy for early prostate cancer Investigators led by Dr. Louis Potters (New York Prostate Institute) enrolled 1449 men with T1b-T2c prostate cancer between 1991 and 2000 and treated with permanent brachytherapy. In actuarial...
Toremifene may lower the risk of prostate cancer in men with PIN (prostate intraepithelial neoplasia) Approximately 9% of all prostate biopsies render e histological changes of PIN - a pre-cancerous condition; on average 60% of those with high grade PIN will progress to cancer by two years (75% by...
Finasteride/proscar reduces the incidence of prostate cancer Finasteride is an alpha reductase inhibitor which has been used for some years to reduce the development of benign prostatic hypertrophy and alleviate some of its symptoms. This enzyme catalyses the...
High tissue inhibitor of metalloproteinases (timp 1) levels may promote prostate cancer invasiveness High TIMP 1 levels have been associated with poor prognosis in studies of breast and colon cancer. Now, researchers from Lousiana have established that high levels in prostate cancer were associated...
Atrasentin, an Endothelin A (et-a) receptor antagonist, may inhibit prostate cancer metastases in bone Osteoblastic (white on x-ray) bone metastases are characteristic of prostate cancer. Endothelin-1 (ET-1) plays a key role in bone-tumour interactions, producing the osteoblastic phenotype (via...
Sexual potency after prostate cancer treatment Dr. J. W. Robinson reported a study (at the 42nd Annual meeting of the American Society for Therapeutic Radiology and Oncology) of the ability of men, treated for early prostate cancer, to maintain...

Page : [1] [2]

« Previous | Next »